Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
400+ patents for cannabinoids and THC, mean the future looks bright for OCTP as soon as their MHRA approval lands:
https://www.globenewswire.com/news-release/2023/03/08/2623044/0/en/Medical-Marijuana-Market-Size-to-Hit-USD-248-42-Billion-by-2030-at-31-97-CAGR-Report-by-Market-Research-Future-MRFR.html
Yep, 427+ cannabinoid patents. Surely they must have one of the biggest , if not the biggest cannabinoid library. Must be worth a fortune to a big pharma or super rich investor looking for a jewel in their crown!
- MHRA approval
- US and Australian research partners confirmed
- Australian Medical Council and FDA applications submitted
- Government or research award non-dilutive grants
- Non-dilutive funding raised through the likes of Finncap
- Australian partner confirms that they will pay to develop programme 2 with no cost to the company or shareholders, with a view that they will offer a license payment system (similar systems tend to be £500m with milestone payments for sales, new offshot lines etc)
- Funding partners secured for programmes 3 and 4
- New programmes confirmed as ready to move through to trials
- New NED’s joining the board
- New 8.3’s, 8.5’s and TR1’s for new and increased holdings
- Applications to list on the Australian and US stock exchanges
- Buy out takeover offer received for 1 programme, the 4 programmes, the entire patent library, or the company as a whole
Absolutely crazy day and good to see the value of this company moving back up to where it deserves to be. Shareprofits have noted a price target back up to 2p by the end of the month, but it wouldn’t surprise me if it hits tomorrow, then fly’s on MHRA news!
Looks like FOMO for if MHRA approval lands for cannabinoid and thc live trials with fully patented technology, which based on similar companies could be worth billions to the global consumer market for a company with a valuation currently less than £10m
New MM’s have entered the arena. Could we finally have that MHRA approval we’ve been waiting for?
Judging by your loss of funds in other stocks, you’re not having much luck being an investor “no.bob”. Your physic abilities have clearly failed you and you missed the bottom entry point back in December.
You joined the telegram group raf?
Please let me know if they come back to you. There is no reason why it should take so long to answer basic questions and perhaps the NED need to do some more due diligence.
I'm also waiting for updates on this construction project they allegedly started and 2 property sales which should be en route to completion.
I also noticed that Paul is still running his gin company, no doubt also using the facilities and equipment that we've paid for, so your concerns are very much warranted.
MHRA are reporting delays in response times, after they’ve had over 1,500 cannabis related applications, many of which are related to farming and don’t meet the requirements, yet they have to respond to each compliance item which takes up a significant amount of time. This will no doubt result in a delay to our assessment review also.
In their latest interview, Val notes when it came to the REC assessment, they had to submit over 35 pieces of documentation and they seemed very happy, which reassures me massively. That’s a massive pack for anyone assessing the company!
Just a waiting game now :)
Great spot. Definitely shows that government funding opportunities are available and that they’re focusing on the benefits of cannabinoids. It seems like Jazz are the lead on this one, but the professors at Oxford Uni are very interlinked with OCTP (it’s a very incestueus industry). No doubt OCTP will be applying for similar grants once they get their phase 1 approval :)
https://news.sky.com/story/cbd-treatment-for-psychosis-to-be-tested-in-major-international-study-12812149
Sorry Kwota was just reading through the messages. The new company set up by the Directors has been confirmed as being a new subsidiary of the main group. It explains it with-in the buying of the facility RNS and that it will focus on the hydroponics part of the business with-in that subsidiary. I reread it last night as it’s noted in the middle of a big brief and even I overlooked it.